Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.9 million.

  • Tonix Pharmaceuticals Holding's Share-based Compensation rose 85.26% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 13.51%. This contributed to the annual value of $4.8 million for FY2024, which is 48.49% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Share-based Compensation is $1.9 million, which was up 35.14% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Share-based Compensation ranged from a high of $2.8 million in Q1 2023 and a low of $882,000 during Q1 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $1.7 million (2024), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Share-based Compensation tumbled by 56.13% in 2024, and later soared by 85.26% in 2025.
  • Tonix Pharmaceuticals Holding's Share-based Compensation (Quarterly) stood at $2.0 million in 2023, then tumbled by 56.13% to $894,000 in 2024, then spiked by 85.26% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.4 million for Q2 2025, and $882,000 during Q1 2025.